Alexopoulou Lena, Irla Magali
Aix Marseille University, CNRS UMR7280, INSERM U1104 Centre d'immunologie de Marseille-Luminy (CIML), Marseille, France.
Elife. 2025 Sep 2;14:e106443. doi: 10.7554/eLife.106443.
The long-term functional adaptation of innate immune cells following an initial stimulation, referred to as trained immunity or innate immune memory, enhances responsiveness and protection against secondary infections. Toll-like receptors (TLRs), an evolutionarily conserved family, recognize microbial-associated molecular patterns, initiating innate and adaptive immune responses. TLR signaling cascades induce the production of pro-inflammatory cytokines, antimicrobial peptides, and interferons, promoting pathogen clearance, while also driving epigenetic and metabolic reprogramming that enhances immune responses and protection to subsequent challenges. However, TLRs also recognize endogenous ligands contributing to chronic inflammation and autoimmune diseases. This review examines the role of TLRs and their various agonists in mediating trained immunity across diverse immune cell types, with an emphasis on their dual role in protecting against infections and chronic inflammation. It highlights recent clinical trials of TLR agonists as immunomodulatory agents and their therapeutic potential in infectious diseases and cancer. By providing an in-depth analysis of TLR-driven trained immunity, this review highlights the extensive influence of TLRs on immune cell populations and their implications for the development of novel, broad-spectrum immunotherapies.
初始刺激后固有免疫细胞的长期功能适应性,即所谓的训练免疫或固有免疫记忆,可增强反应性并抵御二次感染。Toll样受体(TLR)是一个进化上保守的家族,可识别微生物相关分子模式,启动固有免疫和适应性免疫反应。TLR信号级联诱导促炎细胞因子、抗菌肽和干扰素的产生,促进病原体清除,同时还驱动表观遗传和代谢重编程,增强免疫反应并抵御后续挑战。然而,TLR也识别导致慢性炎症和自身免疫性疾病的内源性配体。本综述探讨了TLR及其各种激动剂在介导不同免疫细胞类型的训练免疫中的作用,重点关注它们在抵御感染和慢性炎症中的双重作用。它强调了TLR激动剂作为免疫调节剂的近期临床试验及其在传染病和癌症中的治疗潜力。通过对TLR驱动的训练免疫进行深入分析,本综述突出了TLR对免疫细胞群体的广泛影响及其对新型广谱免疫疗法开发的意义。
Elife. 2025-9-2
Adv Exp Med Biol. 2025
Medicine (Baltimore). 2016-6
Sci China Life Sci. 2025-2-14
J Innate Immun. 2025
J Virol. 2025-5-14
Elife. 2025-8-1
J Clin Invest. 2025-9-2
Front Immunol. 2024-12-10
J Leukoc Biol. 2025-3-14
Curr Opin Immunol. 2024-12
J Immunol. 2024-10-15
Viruses. 2024-5-28
MedComm (2020). 2024-4-29